R(+) zileuton

Drug Profile

R(+) zileuton

Latest Information Update: 09 Jun 2015

Price : $50

At a glance

  • Originator Critical Therapeutics
  • Developer Chiesi USA
  • Class Antiasthmatics; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 11 Apr 2011 Clinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top